Changchun High & New Technology Industries Group's (SHE:000661) unit, Shanghai Saizen Medical Technology, received a medical device registration certificate from the drug regulator of China's Shanghai province for one of its detection kits, the pharmaceutical company said in a Tuesday filing on the Shenzhen Stock Exchange.
The certificate, valid until June 13, 2029, is for an insulin-like growth factor binding protein 3 (IGFBP-3) detection kit (fluorescence immunochromatography), the filing added.
Price (RMB): ¥101.97, Change: ¥-0.41, Percent Change: -0.40%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments